NEW YORK (GenomeWeb News) – Med Biogene today said that it had a loss of C$120,701 (US$117,357) for the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm had EPS of breakeven, compared to a loss of C$196,551, or breakeven EPS, a year ago.

Med Biogene did not disclose its revenues for the quarter and its quarterly earnings document was not yet available online from Canadian regulators.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.